Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Anesthesiology
2014 Aug 01;1212:290-301. doi: 10.1097/ALN.0000000000000268.
Show Gene links
Show Anatomy links
Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology.
Pejo E
,
Santer P
,
Jeffrey S
,
Gallin H
,
Husain SS
,
Raines DE
.
???displayArticle.abstract???
BACKGROUND: R-etomidate possesses unique desirable properties but potently suppresses adrenocortical function. Consequently, efforts are being made to define structure-activity relationships with the goal of designing analogues with reduced adrenocortical toxicity. The authors explored the pharmacological impact of modifying etomidate's chiral center using R-etomidate, S-etomidate, and two achiral etomidate analogues (cyclopropyl etomidate and dihydrogen etomidate).
METHODS: The γ-aminobutyric acid type A receptor modulatory potencies of drugs were assessed in oocyte-expressed α1(L264T)β3γ2L and α1(L264T)β1γ2L γ-aminobutyric acid type A receptors (for each drug, n = 6 oocytes per subtype). In rats, hypnotic potencies and durations of action were measured using a righting reflex assay (n = 26 to 30 doses per drug), and adrenocortical potencies were quantified by using an adrenocorticotropic hormone stimulation test (n = 20 experiments per drug).
RESULTS: All four drugs activated both γ-aminobutyric acid type A receptor subtypes in vitro and produced hypnosis and suppressed adrenocortical function in rats. However, drug potencies in each model ranged by 1 to 2 orders of magnitude. R-etomidate had the highest γ-aminobutyric acid type A receptor modulatory, hypnotic, and adrenocortical inhibitory potencies. Respectively, R-etomidate, S-etomidate, and cyclopropyl etomidate were 27.4-, 18.9-, and 23.5-fold more potent activators of receptors containing β3 subunits than β1 subunits; however, dihydrogen etomidate's subunit selectivity was only 2.48-fold and similar to that of propofol (2.08-fold). S-etomidate was 1/23rd as potent an adrenocortical inhibitor as R-etomidate.
CONCLUSION: The linkage between the structure of etomidate's chiral center and its pharmacology suggests that altering etomidate's chiral center may be used as part of a strategy to design analogues with more desirable adrenocortical activities and/or subunit selectivities.
Albert,
The effect of etomidate on adrenal function in critical illness: a systematic review.
2011, Pubmed
Albert,
The effect of etomidate on adrenal function in critical illness: a systematic review.
2011,
Pubmed
Allolio,
Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome.
1988,
Pubmed
Chan,
Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*.
2012,
Pubmed
Chiara,
Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human α1β3γ2 γ-aminobutyric acid type A (GABAA) receptor.
2013,
Pubmed
Colvin,
Cardiorespiratory changes following induction of anaesthesia with etomidate in patients with cardiac disease.
1979,
Pubmed
Cotten,
Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.
2009,
Pubmed
,
Xenbase
Cotten,
Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.
2010,
Pubmed
,
Xenbase
Davies,
Modulation by general anaesthetics of rat GABAA receptors comprised of alpha 1 beta 3 and beta 3 subunits expressed in human embryonic kidney 293 cells.
1997,
Pubmed
Duthie,
Effect of induction of anaesthesia with etomidate on corticosteroid synthesis in man.
1985,
Pubmed
Forman,
Clinical and molecular pharmacology of etomidate.
2011,
Pubmed
GODEFROI,
DL-1-(1-ARYLALKYL)IMIDAZOLE-5-CARBOXYLATE ESTERS. A NOVEL TYPE OF HYPNOTIC AGENTS.
1965,
Pubmed
Ge,
Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite.
2012,
Pubmed
,
Xenbase
Ge,
Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs.
2012,
Pubmed
Gooding,
Effect of etomidate on the cardiovascular system.
1977,
Pubmed
Hall,
Stereoselective and non-stereoselective actions of isoflurane on the GABAA receptor.
1994,
Pubmed
Heykants,
Distribution, metabolism and excretion of etomidate, a short-acting hypnotic drug, in the rat. Comparative study of (R)-(+)-(--)-Etomidate.
1975,
Pubmed
Hill-Venning,
Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor.
1997,
Pubmed
,
Xenbase
Husain,
Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action.
2012,
Pubmed
JONES,
The synthesis of 5-imidazolecarboxylates from glycine and substituted glycine esters.
1949,
Pubmed
Jackson,
Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal.
2005,
Pubmed
Janssen,
Etomidate, a potent non-barbiturate hypnotic. Intravenous etomidate in mice, rats, guinea-pigs, rabbits and dogs.
1975,
Pubmed
Jurd,
General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit.
2003,
Pubmed
Kissin,
The indices of potency for intravenous anaesthetics.
1981,
Pubmed
Komatsu,
Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery.
2013,
Pubmed
Lamalle,
Cardiovascular effects of various anesthetics in man. Four short-acting intravenous anesthetics: althesin, etomidate, methohexital and propanidid.
1976,
Pubmed
Ledingham,
Influence of sedation on mortality in critically ill multiple trauma patients.
1983,
Pubmed
Li,
Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.
2006,
Pubmed
Morgan,
Etomidate, a new water-soluble non-barbiturate intravenous induction agent.
1975,
Pubmed
Schulte,
Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.
1990,
Pubmed
Sneyd,
Novel etomidate derivatives.
2012,
Pubmed
Soh,
Etomidate in the emergency management of hypercortisolemia.
2012,
Pubmed
Sonegawa,
Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3h-cycloheptimidazol-4-ones and 2-alkyl-3h-cycloheptimidazol-4-ones.
2006,
Pubmed
Sonner,
Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration.
2003,
Pubmed
Tomlin,
Stereoselective effects of etomidate optical isomers on gamma-aminobutyric acid type A receptors and animals.
1998,
Pubmed
Voss,
The howling cortex: seizures and general anesthetic drugs.
2008,
Pubmed
Wagner,
Inhibition of adrenal steroidogenesis by the anesthetic etomidate.
1984,
Pubmed
Wagner,
Etomidate inhibits adrenocortical function in surgical patients.
1984,
Pubmed
Waki,
Efficient preparation of N alpha-formylamino acid tert-butyl esters.
1977,
Pubmed
Watt,
Mortality amongst multiple trauma patients admitted to an intensive therapy unit.
1984,
Pubmed
Waud,
On biological assays involving quantal responses.
1972,
Pubmed
Yip,
A propofol binding site on mammalian GABAA receptors identified by photolabeling.
2013,
Pubmed
Zolle,
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.
2008,
Pubmed
de Jong,
Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation.
1984,
Pubmed
den Brinker,
One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis.
2008,
Pubmed
